Stockscreener 앱 받기
154.79
0.35%
-0.705
Natera Inc 주식(NTRA)의 최신 뉴스
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - Stock Titan
Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas - Medical Device Network
Natera (NTRA) Highlights Promising Study Results for Sarcoma Detection | NTRA Stock News - GuruFocus
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera | NTRA Stock News - GuruFocus
Breakthrough: Largest-Ever Sarcoma Study Validates Natera's Cancer Detection Test with 93% Accuracy - Stock Titan
Learn to Evaluate (NTRA) using the Charts - news.stocktradersdaily.com
CLASS ACTION: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses over $250,000 to Contact the Firm - Newsfile
Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action - TradingView
Natera to Report its First Quarter Results on May 8, 2025 - BioSpace
Natera’s chief legal officer sells $303,299 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 By Investing.com - Investing.com Canada
Natera president Solomon Moshkevich sells $335,714 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 - Investing.com Australia
Natera co-founder Sheena Jonathan sells $66,808 in stock By Investing.com - Investing.com Canada
Natera co-founder Sheena Jonathan sells $66,808 in stock - Investing.com Australia
Natera’s chief legal officer sells $303,299 in stock - Investing.com
Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study - Yahoo Finance
Minimal Residual Disease Testing Market Outlook 2024-2031 | Growth Led by Myriad, Natera & Guardant - openPR.com
Revolutionary Prospera Heart Test Shows 3X Better Transplant Monitoring Than Traditional Biopsies - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now - Insider Monkey
Natera launches Signatera Genome assay nationwide By Investing.com - Investing.com India
Natera Inc (NTRA) Shares Up 3.01% on Apr 24 - GuruFocus
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test - BioSpace
Natera launches Signatera Genome assay nationwide - Investing.com Australia
Natera, Inc. to Present Data from 8 Studies at 2025 AACR Annual Meeting - marketscreener.com
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting - BioSpace
Natera CFO Michael Burkes Brophy sells $88,784 in stock By Investing.com - Investing.com Nigeria
Natera CFO Michael Burkes Brophy sells $88,784 in stock - Investing.com
Natera Executives and Directors Conduct Share Transactions - TradingView
Natera To Present Data from 8 Studies at 2025 AACR Annual Meetin - GuruFocus
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting | NTRA Stock News - GuruFocus
Long Term Trading Analysis for (NTRA) - news.stocktradersdaily.com
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today - Benzinga
The Blood Test Revolution Driving These Three Stocks - Investor's Business Daily
Lobbying Update: $140,000 of NATERA INC lobbying was just disclosed - Nasdaq
When will cancer return? Personalized Signatera blood test can find early signs of disease - Austin American-Statesman
Natera (NasdaqGS:NTRA) Climbs 11% in One Week - simplywall.st
0.96%
자본화:
|
볼륨(24시간):